GlassScriptPhysician profile
Daniel Simon Lefler
NPI 1407219231
$10,528.70
in general payments reported to CMS, 2019-2025
6 companies · $3,788 in 2025
The $3,788 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $6,741 · 2025: $3,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,050 · Honoraria: $2,055 · Food and Beverage: $355 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,050.00 |
| Honoraria | $2,055.00 |
| Food and Beverage | $355.21 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $8,248.41 | 2024-2025 | Ogsiveo |
| Aadi Bioscience, INC. | $2,055.00 | 2024 | |
| Caris Mpi, INC. | $99.35 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Glaxosmithkline, LLC. | $34.65 | 2024 | Zejula, Jemperli |
| Janssen Scientific Affairs, LLC | $22.80 | 2024 | Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lefler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.